Spelling suggestions: "subject:"cervical dysplasia"" "subject:"ervical dysplasia""
11 |
Polymorphisme du papillomavirus humain de type 52 et lésions du col de l'utérusFormentin, Aurélie 08 1900 (has links)
Les papillomavirus humains (VPHs) sont reconnus comme les agents étiologiques du cancer du col de l’utérus. Notre étude a pour but de décrire le polymorphisme de la région régulatrice virale (LCR) et du gène E6 du VPH52 chez 216 femmes canadiennes avec différents grades de lésion du col et d’établir s’il existe une association entre les variantes décrites et la présence de lésions intraépithéliales de haut-grade (CIN2,3) du col de l’utérus ou de cancer invasif. L’âge (OR 1.1, 95% CI 1.02-1.17, p=0.005) fut significativement associé à la présence de cancer invasif. Une variante de la région régulatrice virale, MTL-52-LCR-02, présentant une substitution nucléotidique au niveau du nucléotide 7436, fut aussi associée à la présence de cancer du col de l’utérus (p=0.015). Dans une analyse multivariée, après ajustement pour l’âge, l’ethnicité et le site de recrutement, une délétion au niveau du nucléotide 7695 (OR 5.7, 95% CI 1.2-27.9) ainsi qu’une substitution au niveau du nucléotide 7744 (OR 8.3, 95% CI 1.1-61.0) du LCR, et la variante K93R de la protéine E6 (OR 9.5, 95% CI 1.3-68.9) furent associées de façon significative avec la présence de CIN2,3. Ainsi, le polymorphisme du LCR et du gène E6 du VPH52 est associé avec la présence de CIN2,3 et probablement avec celle d’un cancer invasif. / Human papillomaviruses (HPVs) are the main etiological agents of cervical cancer. Our study aims to describe HPV52 polymorphism in the long control region (LCR) and in the E6 gene, and to investigate the association between LCR and E6 polymorphism and high-grade cervical intraepithelial neoplasia (CIN2,3) or invasive cervical cancer in 216 canadian women with various grades of cervical disease. Age was significantly associated with cervical cancer (OR 1.1, 95% CI 1.02-1.17, p=0.005). The MTL-52-LCR-02 variant, with a nucleotide substitution in the LCR at position 7436, was also associated with cervical cancer. MTL-52-LCR-02 has been identified in 28.6% of women with cervical cancer and in 0.0% of women without cervical cancer or CIN2,3 (p=0.015). In a multivariate analysis, after adjusting for age, ethnicity, detection of HPV16 or 18, and study site, a deletion at nucleotide position 7695 (OR 5.7, 95% CI 1.2-27.9), a variation at nucleotide position 7744 (OR 8.3, 95% CI 1.-61.0) in the LCR and the K93R variant of the protein E6 (OR 9.5, 95% CI 1.3-68.9) were associated with CIN2,3. This study confirms that HPV52 polymorphism in the LCR and in the E6 gene is associated with risk of development of CIN2,3 and possibly invasive cancer of the uterine cervix.
|
12 |
Citologia cérvico-vaginal inflamatória associada com atividade da doença no lúpus eritematoso sistêmico juvenil / Inflammatory cervicovaginal cytology is associated with disease activity in juvenile systemic lupus erythematosusMarília Vieira Febrônio 06 February 2007 (has links)
Objetivo: Avaliar a citologia cérvico-vaginal em adolescentes com lúpus eritematoso sistêmico juvenil (LESJ) e comparar com controles. Material e métodos: Cinqüenta e duas adolescentes com LESJ (critérios do American College of Rheumatology) foram comparadas com 52 controles saudáveis. Todos os esfregaços de Papanicolaou foram avaliados por uma mesma citopatologista, que desconhecia o exame ginecológico, e foram classificados de acordo com o Sistema de Bethesda, 2001. Resultados: As médias das idades das pacientes com LESJ e controles foram similares (16,17 ± 1,94 versus 16,13 ± 2,16 anos, p=0,92). A citologia cérvico-vaginal foi similar em ambos os grupos, embora as relações sexuais no último mês tenham sido menos freqüentes nas pacientes com LESJ em relação aos controles (23% versus 59,6%, p=0,0003). Apenas uma paciente (2%) com LESJ e duas controles (4%) tinham displasia cervical (LIE-BG) e papilomavírus humano (HPV) (p=1,0). Citologia cérvico-vaginal inflamatória foi observada em 21 (60%) das pacientes com SLEDAI maior ou igual a 4 e em apenas 4 (23%) daqueles com SLEDAI < 4 (p=0,001). Assim como, uma maior freqüência de achados inflamatórios também foi observada em adolescentes virgens com LESJ (57% versus 8%, p=0,005). Vaginite por Candida spp foi observada em 7 pacientes com LESJ (14%) e em nenhuma dos controles (p=0,012), e foi associada com uso de drogas imunossupressoras (p=0,01) e dose alta de prednisona (p=0,002). Conclusão: Nossos achados indicam que o trato genital feminino é um órgão alvo no LESJ, pois inflamação cérvico-vaginal está associada com atividade da doença independentemente da atividade sexual. / Objective: To evaluate cervicovaginal cytology in adolescents with juvenile systemic lupus erythematosus (JSLE) and to compare them to controls. Material and methods: Fifty-two female adolescents with JSLE (American College of Rheumatology criteria) were compared to 52 age-matched healthy controls. All Pap smears were evaluated by the same cytopathologist blinded to gynecology examination, and performed according to the Bethesda Classification System 2001. Results: The mean age of JSLE patients and controls were similar (16.17 ± 1.94 vs. 16.13 ± 2.16 years, p=0.92). The cervicovaginal cytology was found to be similar in both groups, although sexual intercourses in the last month were less frequent in JSLE than controls (23% vs. 59.6%, p=0.0003). Only one patient (2%) with JSLE versus two controls (4%) had cervical dysplasia (LGSIL) and human papilomavirus (p=1.0). Inflammatory cervicovaginal cytology was observed in 21 (60%) of patients with SLEDAI ? 4 and only 4(23%) of those with SLEDAI<4 (p=0.001). Likewise, a higher frequency of inflammatory changes were also observed in virgin JSLE (57% vs. 8%, p=0.005). Candida spp vaginitis was observed in 7 JSLE (14%) versus none in controls (p=0.012) and was associated to immunosuppressive drugs (p=0.01) and high dose of prednisone (p=0.002). Conclusion: Our findings supports the notion that female genital tract is a target organ in SLE since cervical inflammation is associated to disease activity independently of sexual activity.
|
13 |
Citologia cérvico-vaginal inflamatória associada com atividade da doença no lúpus eritematoso sistêmico juvenil / Inflammatory cervicovaginal cytology is associated with disease activity in juvenile systemic lupus erythematosusFebrônio, Marília Vieira 06 February 2007 (has links)
Objetivo: Avaliar a citologia cérvico-vaginal em adolescentes com lúpus eritematoso sistêmico juvenil (LESJ) e comparar com controles. Material e métodos: Cinqüenta e duas adolescentes com LESJ (critérios do American College of Rheumatology) foram comparadas com 52 controles saudáveis. Todos os esfregaços de Papanicolaou foram avaliados por uma mesma citopatologista, que desconhecia o exame ginecológico, e foram classificados de acordo com o Sistema de Bethesda, 2001. Resultados: As médias das idades das pacientes com LESJ e controles foram similares (16,17 ± 1,94 versus 16,13 ± 2,16 anos, p=0,92). A citologia cérvico-vaginal foi similar em ambos os grupos, embora as relações sexuais no último mês tenham sido menos freqüentes nas pacientes com LESJ em relação aos controles (23% versus 59,6%, p=0,0003). Apenas uma paciente (2%) com LESJ e duas controles (4%) tinham displasia cervical (LIE-BG) e papilomavírus humano (HPV) (p=1,0). Citologia cérvico-vaginal inflamatória foi observada em 21 (60%) das pacientes com SLEDAI maior ou igual a 4 e em apenas 4 (23%) daqueles com SLEDAI < 4 (p=0,001). Assim como, uma maior freqüência de achados inflamatórios também foi observada em adolescentes virgens com LESJ (57% versus 8%, p=0,005). Vaginite por Candida spp foi observada em 7 pacientes com LESJ (14%) e em nenhuma dos controles (p=0,012), e foi associada com uso de drogas imunossupressoras (p=0,01) e dose alta de prednisona (p=0,002). Conclusão: Nossos achados indicam que o trato genital feminino é um órgão alvo no LESJ, pois inflamação cérvico-vaginal está associada com atividade da doença independentemente da atividade sexual. / Objective: To evaluate cervicovaginal cytology in adolescents with juvenile systemic lupus erythematosus (JSLE) and to compare them to controls. Material and methods: Fifty-two female adolescents with JSLE (American College of Rheumatology criteria) were compared to 52 age-matched healthy controls. All Pap smears were evaluated by the same cytopathologist blinded to gynecology examination, and performed according to the Bethesda Classification System 2001. Results: The mean age of JSLE patients and controls were similar (16.17 ± 1.94 vs. 16.13 ± 2.16 years, p=0.92). The cervicovaginal cytology was found to be similar in both groups, although sexual intercourses in the last month were less frequent in JSLE than controls (23% vs. 59.6%, p=0.0003). Only one patient (2%) with JSLE versus two controls (4%) had cervical dysplasia (LGSIL) and human papilomavirus (p=1.0). Inflammatory cervicovaginal cytology was observed in 21 (60%) of patients with SLEDAI ? 4 and only 4(23%) of those with SLEDAI<4 (p=0.001). Likewise, a higher frequency of inflammatory changes were also observed in virgin JSLE (57% vs. 8%, p=0.005). Candida spp vaginitis was observed in 7 JSLE (14%) versus none in controls (p=0.012) and was associated to immunosuppressive drugs (p=0.01) and high dose of prednisone (p=0.002). Conclusion: Our findings supports the notion that female genital tract is a target organ in SLE since cervical inflammation is associated to disease activity independently of sexual activity.
|
14 |
Polymorphisme du papillomavirus humain de type 52 et lésions du col de l'utérusFormentin, Aurélie 08 1900 (has links)
Les papillomavirus humains (VPHs) sont reconnus comme les agents étiologiques du cancer du col de l’utérus. Notre étude a pour but de décrire le polymorphisme de la région régulatrice virale (LCR) et du gène E6 du VPH52 chez 216 femmes canadiennes avec différents grades de lésion du col et d’établir s’il existe une association entre les variantes décrites et la présence de lésions intraépithéliales de haut-grade (CIN2,3) du col de l’utérus ou de cancer invasif. L’âge (OR 1.1, 95% CI 1.02-1.17, p=0.005) fut significativement associé à la présence de cancer invasif. Une variante de la région régulatrice virale, MTL-52-LCR-02, présentant une substitution nucléotidique au niveau du nucléotide 7436, fut aussi associée à la présence de cancer du col de l’utérus (p=0.015). Dans une analyse multivariée, après ajustement pour l’âge, l’ethnicité et le site de recrutement, une délétion au niveau du nucléotide 7695 (OR 5.7, 95% CI 1.2-27.9) ainsi qu’une substitution au niveau du nucléotide 7744 (OR 8.3, 95% CI 1.1-61.0) du LCR, et la variante K93R de la protéine E6 (OR 9.5, 95% CI 1.3-68.9) furent associées de façon significative avec la présence de CIN2,3. Ainsi, le polymorphisme du LCR et du gène E6 du VPH52 est associé avec la présence de CIN2,3 et probablement avec celle d’un cancer invasif. / Human papillomaviruses (HPVs) are the main etiological agents of cervical cancer. Our study aims to describe HPV52 polymorphism in the long control region (LCR) and in the E6 gene, and to investigate the association between LCR and E6 polymorphism and high-grade cervical intraepithelial neoplasia (CIN2,3) or invasive cervical cancer in 216 canadian women with various grades of cervical disease. Age was significantly associated with cervical cancer (OR 1.1, 95% CI 1.02-1.17, p=0.005). The MTL-52-LCR-02 variant, with a nucleotide substitution in the LCR at position 7436, was also associated with cervical cancer. MTL-52-LCR-02 has been identified in 28.6% of women with cervical cancer and in 0.0% of women without cervical cancer or CIN2,3 (p=0.015). In a multivariate analysis, after adjusting for age, ethnicity, detection of HPV16 or 18, and study site, a deletion at nucleotide position 7695 (OR 5.7, 95% CI 1.2-27.9), a variation at nucleotide position 7744 (OR 8.3, 95% CI 1.-61.0) in the LCR and the K93R variant of the protein E6 (OR 9.5, 95% CI 1.3-68.9) were associated with CIN2,3. This study confirms that HPV52 polymorphism in the LCR and in the E6 gene is associated with risk of development of CIN2,3 and possibly invasive cancer of the uterine cervix.
|
15 |
Análise da prevalência das displasias cervicais e da infecção pelo papilomavírus humano em mulheres com lúpus eritematoso sistêmico / Analysis of cervical dysplasia and woman papillomavirus infection prevalence among women with systemic lupus erythematosusEvandro Mendes Klumb 01 June 2010 (has links)
O lúpus eritematoso sistêmico (LES) que é doença auto-imune com prevalência maior em mulheres, determina lesões potencialmente muito graves em diversos órgãos. Seu tratamento é feito habitualmente com corticosteróides e
agentes citostáticos, sendo esses últimos responsáveis não só por um aumento na freqüência de infecções, mas também de neoplasias, principalmente as hematológicas e as relacionadas às infecções virais. Estudos realizados em
mulheres com LES, evidenciaram maior incidência de displasias cervicais, principalmente as pré-malignas, contudo poucos, pesquisaram especificamente o papiloma vírus humano (HPV) e sua associação com o uso dos imunossupressores. Considerando que a infecção pelo HPV é a doença sexualmente transmissível de maior prevalência no mundo e, que esse vírus é o agente etiológico do câncer
cervical (a segunda neoplasia mais prevalente em mulheres), este estudo foi desenhado com o objetivo de identificar a freqüência da infecção pelo HPV e das displasias cervicais em mulheres com LES incluindo a análise dos fatores de risco
clássicos e o uso de imunossupressores. Neste estudo foram selecionadas 177 pacientes com LES e, 244 mulheres sem LES e sem queixas e/ou doenças ginecológicas conhecidas, atendidas no ambulatório de ginecologia do HUPE-UERJ
ou da Policlínica Piquet Carneiro-UERJ (grupo controle). Todas as mulheres incluídas, foram previamente informadas e assinaram termo de consentimento livre e esclarecido, aprovado pelo Comitê de Ética em Pesquisa do HUPE-UERJ. A
pesquisa do HPV e genotipagem foi feita por reação em cadeia da polimerase e a citopatologia, por coloração de Papanicolaou e análise por dois patologistas. As pacientes com LES apresentaram freqüência da infecção por HPV (20,2%) e de displasias cervicais (22,6%) significativamente mais elevadas que as encontradas no grupo controle (Chi quadrado, P<0,05), apesar de apresentarem em média, menos fatores de risco clássicos para essa infecção (P<0,05). O uso prolongado de imunossupressores, aumentou em três vezes a chance de infecção por HPV dentre as pacientes com LES (cuja prevalência foi de 28,2%). Ainda em referência às
pacientes com LES, as que apresentavam HPV, haviam feito uso de doses cumulativas mais altas de ciclofosfamida e de prednisona e também apresentaram maior razão dose-tempo de azatioprina. Em análise multivariada, incluindo pacientes
e controles, a história de 3 ou mais parceiros sexuais ao longo da vida e o diagnóstico de LES, determinaram aumento de 2 e 6 vezes respectivamente, na prevalência da infecção por HPV. Essas mesmas variáveis também determinaram
um aumento de 3 e 6 vezes na freqüência de displasias cervicais respectivamente. Os resultados obtidos neste estudo demonstram que pacientes com LES, têm maior
freqüência de infecção por HPV e de displasias cervicais principalmente das lesões pré-malignas, e que esse aumento de prevalência é ainda mais significativo para as que receberam imunossupresssores por períodos prolongados. / Systemic lupus erythematosus (SLE) that is an autoimmune disease with higher prevalence among women, causes potencially severe lesions in different organs. SLE treatment commonly includes the use of steroids and cytostatic agents,
being the latter partially responsable for an increased frequency of infection and neoplasia mostly hematologycal and virus-associated cancer. Studies that included women with SLE, have detected higher frequencies of cervical dysplasia, mainly the pre-malignant ones, however few were able to analyse its association with immunosuppressors. Taking into consideration that HPV infection is the most
frequent sexually transmitted disease and that this virus is the etiologycal agent of cervical cancer, the second most prevalent neoplasia among women, this study was designed to detect the frequency of HPV infection and cervical dysplasia in SLE patients and to establish its association with classical risk factors and the use of immunosuppressors. We selected 177 SLE patients and 244 women without SLE
and who did not present any complain or known gynecological disease who attended to the HUPE-UERJ or Policlínica Piquet Carneiro-UERJ gynecology clinics (control
group). All women were previously explained the study and signed an informed consent approved by the HUPE-UERJ Ethical Committee. HPV detection and genotyping were performed by proteinase chain reaction and cytopatology by
Papanicolaou technique with analysis by two pathologists. Patients with SLE presented higher frequency of HPV infection and cervical dysplasia than control group (Chi square, P<0.05), despite they presented less frequently the classical HPV associated risk factors (p<0.05). Long-term use of immunosuppressors determined among LSE patients, a three-fold increase on HPV prevalence (28.2%). Also among
SLE patients, those who presented HPV, have received higher cumulative doses of cyclophosphamide and prednisone and also had a higher dose-time ratio of azathioprine. Multivariate analysis that included all patients and controls, detected
that history of 3 or more life-time sexual partners and the diagnosis of SLE, determined an increase of 2 and 6 times respectively on HPV prevalence. These same variables also determined an increase of 3 and 6 times respectively, on the
prevalence of cervical dysplasya. The findings of the present study confirm that SLE patients have higher frequency of HPV infection and cervical dysplasia, mostly the
pre-malignant and that it is even more significant for those who received immunosuppressors for long periods.
|
16 |
Análise da prevalência das displasias cervicais e da infecção pelo papilomavírus humano em mulheres com lúpus eritematoso sistêmico / Analysis of cervical dysplasia and woman papillomavirus infection prevalence among women with systemic lupus erythematosusEvandro Mendes Klumb 01 June 2010 (has links)
O lúpus eritematoso sistêmico (LES) que é doença auto-imune com prevalência maior em mulheres, determina lesões potencialmente muito graves em diversos órgãos. Seu tratamento é feito habitualmente com corticosteróides e
agentes citostáticos, sendo esses últimos responsáveis não só por um aumento na freqüência de infecções, mas também de neoplasias, principalmente as hematológicas e as relacionadas às infecções virais. Estudos realizados em
mulheres com LES, evidenciaram maior incidência de displasias cervicais, principalmente as pré-malignas, contudo poucos, pesquisaram especificamente o papiloma vírus humano (HPV) e sua associação com o uso dos imunossupressores. Considerando que a infecção pelo HPV é a doença sexualmente transmissível de maior prevalência no mundo e, que esse vírus é o agente etiológico do câncer
cervical (a segunda neoplasia mais prevalente em mulheres), este estudo foi desenhado com o objetivo de identificar a freqüência da infecção pelo HPV e das displasias cervicais em mulheres com LES incluindo a análise dos fatores de risco
clássicos e o uso de imunossupressores. Neste estudo foram selecionadas 177 pacientes com LES e, 244 mulheres sem LES e sem queixas e/ou doenças ginecológicas conhecidas, atendidas no ambulatório de ginecologia do HUPE-UERJ
ou da Policlínica Piquet Carneiro-UERJ (grupo controle). Todas as mulheres incluídas, foram previamente informadas e assinaram termo de consentimento livre e esclarecido, aprovado pelo Comitê de Ética em Pesquisa do HUPE-UERJ. A
pesquisa do HPV e genotipagem foi feita por reação em cadeia da polimerase e a citopatologia, por coloração de Papanicolaou e análise por dois patologistas. As pacientes com LES apresentaram freqüência da infecção por HPV (20,2%) e de displasias cervicais (22,6%) significativamente mais elevadas que as encontradas no grupo controle (Chi quadrado, P<0,05), apesar de apresentarem em média, menos fatores de risco clássicos para essa infecção (P<0,05). O uso prolongado de imunossupressores, aumentou em três vezes a chance de infecção por HPV dentre as pacientes com LES (cuja prevalência foi de 28,2%). Ainda em referência às
pacientes com LES, as que apresentavam HPV, haviam feito uso de doses cumulativas mais altas de ciclofosfamida e de prednisona e também apresentaram maior razão dose-tempo de azatioprina. Em análise multivariada, incluindo pacientes
e controles, a história de 3 ou mais parceiros sexuais ao longo da vida e o diagnóstico de LES, determinaram aumento de 2 e 6 vezes respectivamente, na prevalência da infecção por HPV. Essas mesmas variáveis também determinaram
um aumento de 3 e 6 vezes na freqüência de displasias cervicais respectivamente. Os resultados obtidos neste estudo demonstram que pacientes com LES, têm maior
freqüência de infecção por HPV e de displasias cervicais principalmente das lesões pré-malignas, e que esse aumento de prevalência é ainda mais significativo para as que receberam imunossupresssores por períodos prolongados. / Systemic lupus erythematosus (SLE) that is an autoimmune disease with higher prevalence among women, causes potencially severe lesions in different organs. SLE treatment commonly includes the use of steroids and cytostatic agents,
being the latter partially responsable for an increased frequency of infection and neoplasia mostly hematologycal and virus-associated cancer. Studies that included women with SLE, have detected higher frequencies of cervical dysplasia, mainly the pre-malignant ones, however few were able to analyse its association with immunosuppressors. Taking into consideration that HPV infection is the most
frequent sexually transmitted disease and that this virus is the etiologycal agent of cervical cancer, the second most prevalent neoplasia among women, this study was designed to detect the frequency of HPV infection and cervical dysplasia in SLE patients and to establish its association with classical risk factors and the use of immunosuppressors. We selected 177 SLE patients and 244 women without SLE
and who did not present any complain or known gynecological disease who attended to the HUPE-UERJ or Policlínica Piquet Carneiro-UERJ gynecology clinics (control
group). All women were previously explained the study and signed an informed consent approved by the HUPE-UERJ Ethical Committee. HPV detection and genotyping were performed by proteinase chain reaction and cytopatology by
Papanicolaou technique with analysis by two pathologists. Patients with SLE presented higher frequency of HPV infection and cervical dysplasia than control group (Chi square, P<0.05), despite they presented less frequently the classical HPV associated risk factors (p<0.05). Long-term use of immunosuppressors determined among LSE patients, a three-fold increase on HPV prevalence (28.2%). Also among
SLE patients, those who presented HPV, have received higher cumulative doses of cyclophosphamide and prednisone and also had a higher dose-time ratio of azathioprine. Multivariate analysis that included all patients and controls, detected
that history of 3 or more life-time sexual partners and the diagnosis of SLE, determined an increase of 2 and 6 times respectively on HPV prevalence. These same variables also determined an increase of 3 and 6 times respectively, on the
prevalence of cervical dysplasya. The findings of the present study confirm that SLE patients have higher frequency of HPV infection and cervical dysplasia, mostly the
pre-malignant and that it is even more significant for those who received immunosuppressors for long periods.
|
17 |
Infection with high risk Human Papillomavirus (HRHPV) among HIV-positive women: epidemiology, natural history and impact of combined antiretroviral therapy / Infection par le papillomavirus à haut risque chez les femmes VIH-positives: épidémiologie, histoire naturelle et impact des thérapies antirétrovirales combinéesKonopnicki, Deborah 26 June 2014 (has links)
L’infection persistante par les papillomavirus (HPV) dits « à haut risque » induit le cancer du col. Chez les femmes infectées par le VIH, les infections par ces HPV oncogènes et les lésions associées, allant des dysplasies au cancer invasif, sont plus fréquentes, plus sévères et de moins bon pronostic que chez les femmes non porteuses du VIH. Etonnamment, alors qu’il a été clairement établi que l’importance de la pathologie liée à HPV est directement proportionnelle au degré d’immunodépression des patientes porteuses du VIH, il n’a pas pu être démontré qu’un traitement antirétroviral efficace contre le VIH permettant d’améliorer l’immunité, diminue l’infection par ces HPV. <p>Entre janvier 2002 et décembre 2012, nous avons constitué une cohorte prospective de dépistage et de suivi de l’infection cervicale par HPV à haut risque incluant plus de 900 femmes traitées à la consultation du Centre de Référence SIDA de l’hôpital Saint-Pierre. Nos résultats montrent que chez ces femmes pour la plupart d’origine Africaine et traitée avec succès pour le VIH depuis plusieurs années, la prévalence et l’incidence de l’infection par HPV oncogène sont beaucoup plus importantes que dans la population belge générale ou que chez les femmes séropositives vivant dans d’autres pays occidentaux. Grâce à un suivi longitudinal de plusieurs années, nous avons pu démontrer que le risque d’être infectée par un HPV oncogène est significativement réduit sous trithérapie anti-VIH sous réserve d’obtenir une charge virale indétectable à <50 cp/ml pendant plus de 3 ans ou une restauration immunitaire à >500 lymphocytes CD4+/µL pendant plus d’un an et demi. Ces résultats ont été confirmés dans l’analyse que nous avons faite sur les nombreuses dysplasies cervicales également retrouvées dans notre cohorte. Enfin, nous avons trouvé que la distribution des génotypes d’HPV de nos patientes est similaire à celle trouvée en Afrique sub-saharienne impliquant que la couverture offerte par les vaccins anti-HPV varie entre moins de 30% pour les vaccins bi- ou quadrivalent actuellement disponibles à 80% pour le vaccin nanovalent en développement. Notre travail met en lumière l’étendue particulièrement importante de l’infection par HPV à haut risque chez les femmes séropositives vivant en Belgique et offre de nouveaux éléments de réflexion afin d’adapter à leurs particularités les recommandations belges et les critères de remboursement à la fois pour le dépistage du cancer cervical et la vaccination anti-HPV.<p>/<p>Persistent infection with human papillomavirus (HPV) called “at high risk” induces cervical cancer. In HIV-positive women, infection with these oncogenic HPV and HPV-induced lesions ranging from cervical dysplasia to invasive cancer are more frequent, more severe and have a worst outcome than in HIV-negative women. An intriguing paradox is that, although it has been clearly demonstrated that high risk HPV infection and associated diseases are increased by progressive immune deficiency, the introduction of efficient therapy against HIV leading to improved immunity has not been associated with a decrease in oncogenic HPV infection or HPV-induced lesions.<p>Between January 2002 and December 2012, we have built a prospective cohort to screen and follow-up cervical infection by high risk HPV in more than 900 women treated for HIV in the AIDS Reference centre of Saint-Pierre Hospital. We have shown that among these women mainly from Sub-Saharan African origin and successfully treated for HIV for several years, the prevalence and incidence rate of high risk HPV are much higher than in the general population from Belgium or in HIV-positive women from other western countries. After several years of longitudinal follow up, we have demonstrated that the risk of infection by oncogenic HPV is significantly reduced by efficient therapy against HIV provided that HIV viral load has been sustainly suppressed below 50 cp/ml for more than 3 years or that immunity has been increased more than 500 CD4+T cells/µl for more than 1.5 years. These results have been confirmed in the analysis on cervical dysplasia which is also very prevalent in our cohort. At last, we have found that the HPV genotype distribution in our population is very similar to the one found in Sub-Saharan Africa. We have estimated that the coverage offered by the vaccines against HPV in our cohort is less than 30% for the currently available bi- or quadrivalent vaccine but reaches 80% with the future nanovalent vaccine. Our results highlight many differences in the HPV infection and associated diseases in HIV-positive women compared to HIV-negative women; these differences should be taken into account to adapt to our specific population the current Belgian guidelines or the reimbursement criteria on cervical screening and on vaccines against HPV. <p> / Doctorat en Sciences médicales / info:eu-repo/semantics/nonPublished
|
Page generated in 0.089 seconds